Plasminogen

Plasminogen Overview

Plasminogen is a purified, plasma-derived human zymogen (pro-enzyme) glycoprotein. Chemically, it belongs to the class of organic compounds known as peptides within the amino acids, peptides, and analogues sub-class of carboxylic acids and derivatives. Structurally, it consists of a single-chain polypeptide containing 791 amino acids with five homologous kringle domains, an N-terminal Pan-apple-like domain, and a C-terminal trypsin-like serine protease domain, possessing a molecular weight of approximately 90 kDa.

What Is Plasminogen and How Does It Work?

Plasminogen acts primarily through intravenous systemic replacement of endogenous zymogen, followed by localized cleavage by tPA/uPA into active plasmin (fibrinolysin), driving enzymatic hydrolysis of extravascular fibrin matrices, dissolution of wooden-like ligneous pseudomembranous lesions, and prevention of corneal perforation and airway obstruction.

Is Plasminogen FDA Approved?

Plasminogen (as human plasminogen-tvmh, 68.8 mg lyophilized vial) was approved by the US FDA on June 4, 2021, under the trade name Ryplazim. It holds FDA Orphan Drug Designation, Fast Track status, and Rare Pediatric Disease Designation. Its current regulatory status is FDA Approved.

What Was/Is Plasminogen Used For?

• Systemic replacement therapy for the treatment of pediatric and adult patients with Type 1 Plasminogen Deficiency (hypoplasminogenemia).
• Prevention and active resolution of ligneous conjunctivitis, corneal scarring, and visual loss secondary to ocular mucosal fibrin deposition.
• Prevention of recurrent mucosal lesion formation following surgical excision in hypoplasminogenemic patients.

Before Taking Plasminogen: Contraindications & Precautions

Do not administer Plasminogen to patients with a known severe hypersensitivity to human plasminogen-tvmh, plasma-derived blood products, or formulation excipients (such as sodium citrate, citric acid, and trehalose). Crucial Clinical Warning: Plasminogen infusion accelerates tissue fibrinolysis, causing rapid dissolution of existing ligneous lesions. Rapid dissolution of bronchial, gastrointestinal, or urinary tract pseudomembranes can trigger acute localized bleeding, tissue sloughing, airway obstruction (from sloughed bronchial membranes), or hematuria. Monitor patients closely for bleeding and respiratory compromise during initial dosing cycles.

Who Should Not Take Plasminogen?

• Individuals with known severe hypersensitivity or anaphylactic reaction to human plasminogen, human plasma products, or formulation excipients.
• Patients with active, life-threatening internal hemorrhage unrelated to hypoplasminogenemia.

Plasminogen, Pregnancy & Safety

Systemic human plasminogen is an endogenous human plasma glycoprotein. Plasminogen requirements increase during normal pregnancy to support placental fibrin turnover. Controlled clinical trials evaluating Ryplazim in pregnant women are lacking. Animal reproduction studies evaluating human plasminogen-tvmh have not been formally conducted.

Tell Your Doctor Before Taking Plasminogen

Inform your hematologist, ophthalmologist, or physician if you have a history of severe bleeding disorders, active respiratory tract lesions, recent surgical procedures, kidney disease, or severe allergic reactions to blood products.

Plasminogen Dosage & Administration

Formulated as a sterile, lyophilized, single-dose powder vial (68.8 mg human plasminogen-tvmh) requiring reconstitution with 12.5 mL of Sterile Water for Injection (SWFI) to yield a 5.5 mg/mL solution.

Standard Plasminogen Dosing

• Type 1 Plasminogen Deficiency Baseline Initial Dosing (Pediatric & Adult Patients): Administered as 6.6 mg/kg body weight intravenously every 2 to 4 days (infused over 10 to 30 minutes at a maximum rate of 5 mL/min).
• Trough Level Monitoring & Dose Adjustment Protocol:

• Obtain a baseline trough plasminogen activity level prior to initiation.
• Obtain a trough plasminogen activity level at least 72 hours post-infusion following the second dose.
• If trough plasminogen activity is < 30% of normal: Increase frequency to every 2 days or increase dose in 1.0 mg/kg increments up to a maximum of 12.0 mg/kg every 2 to 4 days.
• Target trough plasminogen activity level: Maintain trough activity ≥ 30% above baseline (or absolute activity ≥ 30–50%).

How Was/Is Plasminogen Administered

• Reconstitution Procedure: Bring vial and SWFI to room temperature; reconstitute with 12.5 mL SWFI, gently swirling the vial in a circular motion (do not shake) until fully dissolved.
• Administer through a dedicated intravenous line equipped with a sterile, inline, low-protein-binding 0.2 μm or 0.22 μm filter. Infuse over 10 to 30 minutes (do not exceed 5 mL/min).

Plasminogen Clinical Efficacy & Research

In clinical trial research for rare metabolic disorders, Plasminogen (Ryplazim) is established as a disease-modifying therapy. The pivotal Phase II/III open-label, single-arm clinical trial evaluated 15 pediatric and adult patients with Type 1 Plasminogen Deficiency over 48 weeks of intravenous Ryplazim therapy (6.6 mg/kg every 2 to 4 days). Results demonstrated 100% clinical efficacy: all 15 patients achieved a mean trough plasminogen activity level increase of ≥ 30% above baseline.

Plasminogen Side Effects & Safety Profile

Plasminogen exhibits a favorable clinical safety profile. Safety hazards stem primarily from infusion-related reactions, tissue sloughing during lesion dissolution, and minor localized bleeding.

Adverse effects correlate directly with systemic fibrinolysis and protein administration.

Common Plasminogen Side Effects

• Infusion-Related & General (> 10% incidence): Abdominal pain, bloating, nausea, fatigue, headache, dizziness, arthralgia, back pain, and low-grade fever.
• Mucosal & Dermatological (5% to 10% incidence): Epistaxis (nosebleeds), minor mucosal bleeding, skin rash, pruritus, and localized sloughing of pseudomembranes.

Serious Plasminogen Adverse Events

• Mucosal Lesion Dissolution & Airway Obstruction: Rapid sloughing of large, tracheobronchial or pharyngeal ligneous pseudomembranes causing transient mechanical airway occlusion or severe hemoptysis.
• Gastrointestinal & Genitourinary Hemorrhage: Dissolution of deep mucosal lesions in the bladder or intestine triggering transient hematuria or gastrointestinal bleeding.
• Severe Hypersensitivity & Anaphylaxis: Allergic reactions, dyspnea, hypotension, and anaphylaxis secondary to plasma-derived human protein exposure.
• Neutralizing Antibody Formation: Formation of anti-plasminogen neutralizing antibodies leading to loss of therapeutic response (monitored via falling trough activity levels).

Managing Plasminogen Side Effects

If an infusion-related allergic reaction occurs, slow or stop the IV infusion immediately and administer antihistamines or epinephrine as indicated. If airway pseudomembranes are present, perform baseline bronchoscopy and monitor respiratory function closely during the first 2 weeks. If mucosal bleeding occurs, assess trough plasminogen levels and hold dose temporarily if required.

Plasminogen Drug Interactions & What to Avoid

Plasminogen displays important pharmacodynamic interactions with systemic antifibrinolytics and pro-thrombotic agents.

Co-administration with specific drug classes directly antagonizes or amplifies its fibrinolytic action.

Plasminogen Drug-Drug Interactions

• Antifibrinolytic Agents (Tranexamic Acid, Aminocaproic Acid): Act as direct competitive inhibitors of plasminogen and plasmin by binding to lysine-binding sites on kringle domains; co-administration completely abolishes the therapeutic fibrinolytic activity of Plasminogen; avoid concurrent use.
• Systemic Thrombolytic Agents (Alteplase, Reteplase, Tenecteplase): Exogenous tissue plasminogen activators accelerate the conversion of Ryplazim into plasmin, markedly amplifying systemic fibrinolysis and increasing major bleeding risks.
• Pro-Coagulant Blood Factors (Factor IX Complex, Prothrombin Complex Concentrates): Pharmacodynamically oppose fibrinolytic activity.

Plasminogen, Food & Alcohol

Systemic food interactions do not apply to intravenous administration. Alcohol consumption does not directly alter human plasminogen pharmacokinetics.

Plasminogen: Missed Dose, Overdose & Storage

Proper handling of Plasminogen involves consistent intravenous infusion schedules and strict cold-chain storage. Overdose increases systemic fibrinolysis.

Adherence to proper storage parameters maintains protein folding stability and prevents zymogen degradation.

Missed Dose of Plasminogen

Administer the missed intravenous dose as soon as possible, then resume the regular 2- to 4-day infusion schedule based on trough activity goals. Do not administer a double dose to make up for a missed infusion.

Plasminogen Overdose & Emergency

Systemic overdose of Plasminogen elevates plasma plasminogen activity significantly above normal, increasing the risk of hyper-fibrinolysis and systemic bleeding. Emergency management includes stopping the IV infusion, monitoring complete blood counts and coagulation parameters (PT, aPTT, fibrinogen, D-dimer), and administering systemic antifibrinolytics (tranexamic acid or aminocaproic acid) or fresh frozen plasma if severe, life-threatening hemorrhage occurs.

How to Store Plasminogen

Store unopened Ryplazim 68.8 mg lyophilized vials refrigerated between 2°C and 8°C (36°F to 46°F) in their original carton to protect from light. Do not freeze. Reconstituted Ryplazim solution should be administered immediately; if not used immediately, store reconstituted solution in the vial at 2°C to 8°C for up to 3 hours or at room temperature (20°C to 25°C) for up to 3 hours. Do not freeze reconstituted solution. Keep out of reach of children.

Plasminogen Patient Management & Monitoring

Clinical oversight for patients receiving Plasminogen focuses on obtaining trough plasminogen activity levels, conducting slit-lamp ocular examinations, and evaluating mucosal lesion dissolution.

Regular clinical tracking ensures complete lesion resolution without hyper-fibrinolytic or bleeding complications.

Tests Before Starting Plasminogen

Baseline trough plasminogen activity level and plasminogen antigen concentration; baseline complete blood count (CBC) and coagulation panel (PT, aPTT, fibrinogen); baseline ophthalmologic examination (slit-lamp assessment, fundus photography, corneal staining) to document ligneous conjunctivitis severity; baseline ENT / respiratory tract evaluation to document mucosal lesions.

Monitoring During Plasminogen Treatment

Monitoring trough plasminogen activity level at least 72 hours post-infusion following the second dose, and every 3 to 6 months during maintenance therapy (target: trough activity ≥ 30% above baseline); serial ophthalmologic examinations every 1 to 3 months until complete lesion resolution; serial monitoring for mucosal sloughing or bleeding during initial 12 weeks.

Plasminogen Do’s and Don’ts

• Do receive your Ryplazim IV infusions on a strict 2- to 4-day schedule as prescribed by your hematologist or specialist.
• Do have your trough plasminogen blood activity checked regularly to make sure your dose is keeping your enzyme levels above 30%.
• Do report any sudden nosebleeds, blood in your urine, cough with blood, or respiratory difficulty to your doctor immediately.
• Do not take antifibrinolytic medicines like tranexamic acid (Lysteda) or aminocaproic acid while receiving Ryplazim, as they block the medication from working.
• Do not shake the vial during reconstitution swirl it gently to avoid foaming the protein solution.
• Do not stop Ryplazim infusions prior to surgery without consulting your specialist, as stopping therapy causes rapid lesion recurrence.

Frequently Asked Questions

References

• DrugBank Database – Plasminogen Clinical Profile (DB16701)
• Classyfire Database – Peptides / Carboxylic Acids Taxonomy Profile
• US Food and Drug Administration (FDA) – Ryplazim (Human Plasminogen-tvmh) Prescribing Information & Clinical Review

Legal Disclaimer

The detailed medical and chemical information provided on this specific web page is intended strictly for educational and informational purposes regarding complex pharmacological mechanisms. It absolutely does not constitute professional medical advice, medical diagnosis, or specific treatment recommendations. Always consult a licensed healthcare provider before making any personal decisions regarding complex medical conditions, medication adjustments, or dietary changes.